Becton Dickinson said on Wednesday its board has authorized a plan to separate its life sciences unit as the medical device maker aims to focus on its core business.
As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...
Blockbuster Keytruda makes up nearly half of Merck’s sales. That’s becoming an issue.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback